KAMALJIT ATWAL, DO
Pulmonary Disease Physician in PORTLAND, Oregon. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
KAMALJIT ATWAL, DO reported a CMS MIPS final score of 97.83/100 — above the 83.1 national average — and filed 2,494 Medicare Part D claims in 2023.
- 97.83/100
- MIPS score · +15 vs avg
- 2K
- Part D claims, 2023
- 47%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
KAMALJIT ATWAL, DO's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
98 Top 15% higher than 85% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
KAMALJIT ATWAL, DO practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about KAMALJIT ATWAL, DO?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Oregon
How Pulmonary Disease Physician compares to other specialties among Oregon providers
Pulmonary Disease Physician share within Oregon
Pulmonary Disease Physician is one of the more visible NUCC categories in Oregon
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
KAMALJIT ATWAL, DO's 2023 MIPS final score plotted against the Pulmonary Disease Physician national average
- MIPS Final Score
- 97.83/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Pulmonary Disease Physician) — 97.83/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Pulmonary Disease Physician US NPIs
97.83/100 MIPS final score — 14.7 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Pulmonary Disease Physician. Quality dim: 80.9759.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
KAMALJIT ATWAL, DO appears in the CMS NPPES registry as a Pulmonary Disease Physician provider holding DO credentials at 10201 SE MAIN ST STE 11, PORTLAND, OR, 97216, with a listed phone of (503) 253-2248. NPI 1821053356 was issued on 04/18/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ATWAL most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 2,494 prescription claims written by this provider, covering 337 Medicare beneficiaries and totaling roughly $1.1 million in drug spend, split 53% brand-name and 47% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 97.83/100 for the 2023 performance year (Quality 80.9759), compared with the national average of 83.1.
Pulmonary Disease Physician is a mid-sized specialty nationwide, with 9,271 enrolled providers across 53 states and an average of 1,457 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1821053356 |
|---|---|
| Specialty | Pulmonary Disease Physician |
| Credentials | DO |
| Gender | Female |
| NPI Issued | 04/18/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm KAMALJIT ATWAL, DO's current license status, disciplinary history, and board certifications with the Oregon Medical Board in Oregon before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
Hospital and facility affiliations
Facilities where KAMALJIT ATWAL, DO bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Brand vs generic prescribing mix · Brand-heavy
53% brand-name claims vs 47% generic, on 2,494 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 4,139
- Total Day Supply
- 117,300
- Brand vs Generic
- 53% brand / 47% generic
- Brand Drug Cost
- $1.1M
- Antibiotic Claims
- 125
Patient Demographics
- Average Patient Age
- 73.5 years
- Avg HCC Risk Score
- 1.85
- Gender Split
- 66% female / 34% male
- Age Distribution
- <65: 39, 65-74: 141, 75-84: 120, 85+: 37
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What KAMALJIT ATWAL, DO prescribes most
Top Medicare Part D drugs by claim count, 2023
- Trelegy Ellipta
Trelegy Ellipta
450 claims
- Montelukast Sodium
Montelukast Sodium
318 claims
- Albuterol Sulfate …
Albuterol Sulfate Hfa
281 claims
- Prednisone 144
Prednisone
144 claims
- Breo Ellipta 105
Breo Ellipta
105 claims
- Incruse Ellipta 82
Incruse Ellipta
82 claims
- Spiriva Respimat 72
Spiriva Respimat
72 claims
- Azithromycin 69
Azithromycin
69 claims
| Drug | Claims |
|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 450 |
| Montelukast Sodium | 318 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 281 |
| Prednisone | 144 |
| Breo Ellipta Fluticasone/Vilanterol | 105 |
| Incruse Ellipta Umeclidinium Bromide | 82 |
| Spiriva Respimat Tiotropium Bromide | 72 |
| Azithromycin | 69 |
| Advair Hfa Fluticasone Propion/Salmeterol | 65 |
| Symbicort Budesonide/Formoterol Fumarate | 62 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pulmonary Disease Physician Overview
How KAMALJIT ATWAL, DO fits within the Pulmonary Disease Physician landscape nationally.
KAMALJIT ATWAL, DO's 2,494 claims are above the specialty average of 1,457.
Nearby Pulmonary Disease Physician Providers in Oregon
Other clinicians with the same primary specialty enrolled in Oregon, drawn from the same CMS NPPES roster as ATWAL.
Compare Pulmonary Disease Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Oregon
Frequently Asked Questions
What is KAMALJIT ATWAL, DO's specialty? ▼
How much does KAMALJIT ATWAL, DO prescribe under Medicare Part D? ▼
What is KAMALJIT ATWAL, DO's Medicare quality score? ▼
Where is KAMALJIT ATWAL, DO located? ▼
What is KAMALJIT ATWAL, DO's NPI number? ▼
Does KAMALJIT ATWAL, DO prescribe more brand-name or generic drugs? ▼
How many Pulmonary Disease Physician providers are there in the US? ▼
What drugs does KAMALJIT ATWAL, DO prescribe most often? ▼
Does KAMALJIT ATWAL, DO accept Medicare? ▼
How can I verify KAMALJIT ATWAL, DO's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology